

# FDA says no to anturane

Science

208, 1130-1132

DOI: [10.1126/science.6990491](https://doi.org/10.1126/science.6990491)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Statistics and ethics in medical research. Collecting and screening data.. BMJ: British Medical Journal, 1980, 281, 1399-1401.	2.4	19
2	ANTIPLATELET DRUGS IN THE SECONDARY PREVENTION OF MYOCARDIAL INFARCTION. Lancet, The, 1980, 316, 736-738.	6.3	9
3	Therapy or Research: A Need for Precision. IRB: Ethics & Human Research, 1981, 3, 1.	0.8	4
4	Sulfinpyrazone and aspirin increase epicardial coronary collateral flow in dogs. American Journal of Cardiology, 1981, 47, 848-854.	0.7	10
5	Hemostasis, Thrombosis, and Thromboembolic Disorders: The Role of Arachidonic Acid Metabolites in Platelet-Vessel Wall Interactions. Medical Clinics of North America, 1981, 65, 855-880.	1.1	57
6	Mechanisms of Hemostasis and Therapy of Thrombosis: New Concepts Based on the Metabolism of Arachidonic Acid by Platelets and Endothelial Cells. Advances in Pharmacology, 1981, 18, 1-47.	1.2	20
7	The randomized clinical trial: bias in analysis.. Circulation, 1981, 64, 669-673.	1.6	151
8	Recent advances in cardiology.. Postgraduate Medical Journal, 1982, 58, 459-466.	0.9	1
9	Design of Clinical Trials. Drug Information Journal, 1982, 16, 44-50.	0.5	0
10	ANTIPLATELET AGENTS: THEIR ROLE IN THE PREVENTION OF SUDDEN DEATH. Annals of the New York Academy of Sciences, 1982, 382, 289-304.	1.8	3
11	The effect of coronary bypass surgery on survival. Progress in Cardiovascular Diseases, 1983, 25, 297-334.	1.6	25
12	The natural history of coronary artery disease: Does medical therapy improve the prognosis?. Progress in Cardiovascular Diseases, 1983, 25, 513-552.	1.6	11
13	Dose-related cardiac electrophysiologic effects of sulfinpyrazone. Clinical Pharmacology and Therapeutics, 1985, 37, 166-173.	2.3	4
14	Determination of sulfinpyrazone and four metabolites in plasma and urine by high pressure liquid chromatography. Pharmaceutisch Weekblad, 1985, 7, 252-259.	0.7	1
15	Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.. Circulation, 1986, 73, 206-223.	1.6	57
16	Antithrombotic Agents in Coronary Artery Disease. Chest, 1986, 89, 54S-67S.	0.4	20
17	Platelets and antiplatelet therapy in ischemic heart disease. Current Problems in Cardiology, 1986, 11, 72-136.	1.1	12
18	The ischemic heart disease life stress monitoring program: Possible therapeutic mechanisms. Psychology and Health, 1987, 1, 273-285.	1.2	11

#	ARTICLE	IF	CITATIONS
19	Analytic Reviews : Antithrombotic Tberapy in Acute Myocardial Infarction and Unstable Angina. Journal of Intensive Care Medicine, 1987, 2, 299-312.	1.3	1
20	Platelets and Antiplatelet Therapy in Ischemic Heart Disease. Medical Clinics of North America, 1988, 72, 117-184.	1.1	17
21	Antithrombotic Agents in Coronary Artery Disease. Chest, 1989, 95, 52S-72S.	0.4	41
22	Heparin and Secondary Prevention of Acute Myocardial Infarction. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1990, 20, 132-141.	0.5	0
23	Randomised Controlled Clinical Trials. , 1996, , .		27
24	Essentials of Randomized Clinical Trials. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 254-259.	0.5	0
25	Antiplatelet Agents: Rationale and Results. Clinics in Haematology, 1983, 12, 311-354.	2.2	26
26	The Value of Drugs that Modify Platelet and Vessel Wall Function for the Clinical Complications of Atherosclerosis. , 1980, , 242-247.		0
27	Strategies for Improving the Efficiency of Long-Term Intervention Studies. , 1981, , 123-133.		0
30	Thrombosis: its role and prevention in cardiovascular events-Part II. Western Journal of Medicine, 1981, 134, 315-32.	0.3	0